Clinical trials: Sinonasal Undifferentiated Carcinoma
Sinonasal Cancer, Paranasal Sinus Neoplasms
Toripalimab With Chemotherapy for Sinus Cancer
The aim of this research study is to evaluate the effectiveness and safety of a combination of immunotherapy, using a drug called toripalimab, with chemotherapy drugs, Carboplatin and Docetaxel, as a possible treatment before…
- Conditions
- Sinonasal Cancer, Paranasal Sinus Neoplasms, Squamous Cell Carcinoma, Sinonasal Undifferentiated Carcinoma
- Trial name
- NCT06940180
- Testing
- Toripalimab, Carboplatin, Docetaxel
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- Dana-Farber Cancer Institute
Metastatic Chondrosarcoma, Locally Advanced Chondrosarcoma
Enasidenib in IDH2-Mutated Malignant Sinonasal and Skull Base Tumors
Background: Cancers of the nasal cavity or skull base are rare. They often are not diagnosed until they are at an advanced stage, and they often spread to other parts of the body.
- Conditions
- Metastatic Chondrosarcoma, Locally Advanced Chondrosarcoma, Metastatic Sinonasal Adenocarcinoma, Locally Advanced Sinonasal Adenocarcinoma
- Trial name
- NCT06176989
- Testing
- Enasidenib
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- National Cancer Institute (NCI)
Melanoma, Medullary Thyroid Cancer
Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors
Phase I study to examine safety of the addition of concurrent tarlatamab with standard palliative and consolidative RT regimens , with a main cohort of N=20-24 patients with extracranial anatomic radiation sites.
- Conditions
- Melanoma, Medullary Thyroid Cancer, Sinonasal Undifferentiated Carcinoma, Esthesioneuroblastoma
- Trial name
- RABBIT (NCT06814496)
- Testing
- Tarlatamab, Concurrent Radiation Therapy, Sequential Radiation therapy
- Where
- 3 sites in United States
- Volunteers
- 30 people
- Sponsor
- University of Arizona
Sinonasal Undifferentiated Carcinoma
Pembrolizumab in Locally Advanced Sinonasal Carcinoma
This study will test the Safety and activity of pembrolizumab plus chemotherapy as neoadjuvant treatment in locally advanced sinonasal undifferentiated carcinoma (SNUC).
- Trial name
- NeoPeSino (NCT05925491)
- Testing
- Pembrolizumab, Cisplatin, Docetaxel
- Where
- Italy
- Volunteers
- 28 people
- Sponsor
- Istituti Clinici Scientifici Maugeri SpA
Adenoid Cystic Carcinoma, Squamous Cell Carcinoma
Intensity-Modulated or Proton Radiation Therapy for Sinonasal Malignancy
The purpose of this study is to test the hypothesis that 1)intensity-modulated radiotherapy (IMRT) or proton radiation therapy would result in improved local control rate and lowered toxicity compared to conventional…
- Conditions
- Adenoid Cystic Carcinoma, Squamous Cell Carcinoma, Sinonasal Carcinoma, Sinonasal Undifferentiated Carcinoma
- Trial name
- NCT01586767
- Testing
- Proton radiation therapy, Intensity-modulated radiotherapy
- Where
- 2 sites in United States
- Volunteers
- 45 people
- Sponsor
- Massachusetts General Hospital
Locally Advanced Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma, Nasal Cavity and Paranasal Sinus Poorly Differentiated Carcinoma
Docetaxel, Cisplatin and Fluorouracil in Treating Patients With Previously Untreated Stage II-IV Nasal Cavity and Paranasal Sinus Cancer
This phase II trial studies how well docetaxel, cisplatin and fluorouracil work in treating patients with previously untreated stage II-IV nasal cavity and/or paranasal sinus cancer.
- Conditions
- Locally Advanced Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma, Nasal Cavity and Paranasal Sinus Poorly Differentiated Carcinoma, Sinonasal Undifferentiated Carcinoma, Stage II Nasal Cavity and Paranasal Sinus Cancer AJCC v8
- Trial name
- NCT00707473
- Testing
- Carboplatin, Chemoradiotherapy, Cisplatin
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- M.D. Anderson Cancer Center